DK3159357T3 - Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner - Google Patents

Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner Download PDF

Info

Publication number
DK3159357T3
DK3159357T3 DK16020270.1T DK16020270T DK3159357T3 DK 3159357 T3 DK3159357 T3 DK 3159357T3 DK 16020270 T DK16020270 T DK 16020270T DK 3159357 T3 DK3159357 T3 DK 3159357T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
composition
bacterial infections
enteric bacterial
Prior art date
Application number
DK16020270.1T
Other languages
English (en)
Inventor
Roy Michael Robins-Browne
Grant Thomas Rawlin
Gottfried Lichti
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Application granted granted Critical
Publication of DK3159357T3 publication Critical patent/DK3159357T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16020270.1T 2003-03-04 2004-03-04 Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner DK3159357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901008A AU2003901008A0 (en) 2003-03-04 2003-03-04 Composition for the treatment and prevention of bacterial infections
EP04716992A EP1605975A4 (en) 2003-03-04 2004-03-04 COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ENTERIAN BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
DK3159357T3 true DK3159357T3 (da) 2022-04-04

Family

ID=31500053

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16020270.1T DK3159357T3 (da) 2003-03-04 2004-03-04 Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner

Country Status (10)

Country Link
US (1) US8637025B2 (da)
EP (2) EP3159357B1 (da)
CN (2) CN102698258A (da)
AU (1) AU2003901008A0 (da)
BR (1) BRPI0408085A (da)
CA (1) CA2517911C (da)
DK (1) DK3159357T3 (da)
ES (1) ES2903120T3 (da)
NZ (1) NZ542088A (da)
WO (1) WO2004078209A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053383A1 (en) 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
WO2008148149A1 (en) * 2007-06-05 2008-12-11 Anadis Ltd Method of treatment or inhibition of enterovirus 71 infection
AU2009222965B2 (en) 2008-03-13 2014-10-02 Immuron Limited Immuno-modulating compositions for the treatment of immune-mediated disorders
EA024697B1 (ru) 2009-04-27 2016-10-31 Иммурон Лимитед Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени
CA2808361A1 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of inflammatory bowel disease
AU2011313811A1 (en) * 2010-10-04 2013-01-31 Immuron Limited Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
MX340019B (es) 2010-11-23 2016-06-22 Pantheryx Inc Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas.
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
WO2012171077A1 (en) * 2011-06-17 2012-12-20 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
EP2986316B1 (en) 2013-04-19 2023-01-25 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
GB201312635D0 (en) * 2013-07-15 2013-08-28 Univ Plymouth Water testing
US20150086592A1 (en) * 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2015063693A1 (en) 2013-10-30 2015-05-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
JP6590413B2 (ja) * 2014-02-06 2019-10-16 エックスフォー・ファーマシューティカルズ（オーストリア）ゲーエムべーハー 大腸菌特異的抗体配列
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US11130800B2 (en) 2016-05-20 2021-09-28 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
KR101871338B1 (ko) 2016-12-22 2018-06-26 주식회사 옵티팜 신규한 병원성 대장균 특이 박테리오파지 ec14 및 이를 포함하는 항균 조성물
US12195500B2 (en) 2018-11-13 2025-01-14 Novobind Livestock Therapeutics, Inc. Antibodies against disease causing agents of canines and felines and uses thereof
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
US12263192B2 (en) 2019-02-26 2025-04-01 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
WO2022011436A1 (en) * 2020-07-17 2022-01-20 Immuron Limited Methods of treating coronavirus infection with bovine-hyperimmune colostrum
IL308201A (en) 2020-09-17 2024-01-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
CN112540077B (zh) * 2020-11-30 2022-12-06 邢台学院 一种原位检测种子中脂肪酸不饱和度的方法
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2022241058A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
CN113603761B (zh) * 2021-08-09 2023-03-31 复旦大学附属中山医院 一种用于重症急性胰腺炎肠道功能障碍的小分子多肽
CN114521638A (zh) * 2022-01-25 2022-05-24 安徽妙奇树生物科技股份有限公司 一种具有改善便秘的水果型酵素组合物胶原果冻、果胶及其制备方法
EP4619430A1 (en) 2022-11-16 2025-09-24 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2025184686A1 (en) * 2024-03-05 2025-09-12 Immuron Limited Methods and compositions ii
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376198A (en) 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
GB1560934A (en) 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
NZ201698A (en) * 1981-08-31 1985-12-13 S L Gaffin Composition of antibodies specific to endotoxins
US4971794A (en) * 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
NZ205392A (en) * 1982-09-02 1987-03-06 Unilever Plc Preparation of immunoglobulins against e.coli pili
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US5017372A (en) 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
GB9018061D0 (en) 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
ATE234855T1 (de) 1993-09-20 2003-04-15 Anadis Ltd Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
KR20040106298A (ko) 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법

Also Published As

Publication number Publication date
NZ542088A (en) 2008-04-30
CN102698258A (zh) 2012-10-03
EP1605975A1 (en) 2005-12-21
EP3159357B1 (en) 2022-01-05
CA2517911A1 (en) 2004-09-16
AU2003901008A0 (en) 2003-03-20
EP1605975A4 (en) 2006-04-19
EP3159357A1 (en) 2017-04-26
CN1764476A (zh) 2006-04-26
CA2517911C (en) 2017-06-27
WO2004078209A1 (en) 2004-09-16
ES2903120T3 (es) 2022-03-31
US8637025B2 (en) 2014-01-28
US20070053917A1 (en) 2007-03-08
BRPI0408085A (pt) 2006-02-14

Similar Documents

Publication Publication Date Title
DK3159357T3 (da) Sammensætning og fremgangsmåde til behandling og forebyggelse af enteriske bakterielle infektioner
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
DK1624871T3 (da) Fremgangsmåde til behandling af atherosklerose, dyslipidæmi og relaterede tilstande og farmaceutiske sammensætninger
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
NO20055837D0 (no) Immunsupprimerende forbindelser og sammensetninger
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK1542710T3 (da) Fremgangsmåde til konservering af organer og væv
DK1641436T3 (da) Inhalerbar aztreonamlysinatformulering til behandling af og forebyggelse mod bakterielle lungeinfektioner
EP1562618A4 (en) CYCLOOXYGENASE-2-HEMMENDEWITHANOLID COMPOSITIONS AND METHODS
NO20035562L (no) System og fremgangsmate for forenklet initiering av konferanser
DK1589973T3 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
IS8082A (is) Inndælingarbúnaður án nálar og aðferð til inndælingar
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
EP1660116A4 (en) METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
DK1656143T3 (da) Quinolon-antibiotika til behandling af periodontale infektioner
DK1791423T3 (da) Sammensætninger og fremgangsmåder til behandling af hyperproliferative dermatologiske tilstande
EP1662868A4 (en) PLANT PROTECTION AGENTS AND METHODS
DK2457582T3 (da) Fremgangsmåde og sammensætningertil kontrol af ektoparasitter
FI20031678A0 (fi) Näytteen käsittelymenetelmä ja järjestely siihen